Medical Cannabis: Toward a New Policy and Health Model for an Ancient Medicine

Frontiers in Public Health

article

Davide Fortin¹  Fabienne Marcellin²  Patrizia Carrieri²  Julien Mancini²  Tangui Barré² 

[1] University Paris 1 Sorbonne;Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale

关键词: cannabis;    drug policy;    cannabis flowers;    marijuana;    real-word evidence;    France;    patient-reported outcomes (PROs);   

DOI  :  10.3389/fpubh.2022.904291

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Cannabis has been grown and exploited by mankind for its therapeutic properties since ancient times (1). Although a growing number of countries have approved cannabis-based products for medical use, high-quality evidence for cannabis itself (understood in this article as the unprocessed flowering tops of the plant) in this context is lacking, and only a few jurisdictions to date have approved the medical use of cannabis, mostly as magistral preparations (2). The reason for this lies in the large variation in cannabis material as a plant (3, 4). Real-word data on the medical use of cannabis could be of benefit to patients worldwide, healthcare professionals, policymakers, and researchers (3, 5, 6). In this article, we discuss these points and propose that the collection of patient-reported outcomes (PROs) could be a cornerstone of a medical cannabis policy.

【 授权许可】

CC BY